
Extended Culture of Blastocysts: Advantages and Disadvantages and In Which Patients?

Catherine Racowsky, PhD, HCLD/ELD(ABB) cracowsky@bwh.harvard.edu



Professor of Obstetrics & Gynecology Harvard Medical School Brigham and Women's Hospital Boston, MA



2017 AAB Educational Conference/21st Annual CRB Symposium Westin Galleria Hotel, Houston, Texas May 17th-19th, 2017

DISCLOSURES

- Catherine Racowsky, PhD, HCLD
- Extended culture of blastocyst: Advantages and disadvantages & which patients?

FINANCIAL DISCLOSURES (during last 12 months)

- Consultant: World Health Organization LifeGlobal, Inc
- Speaker's Bureau: Ferring Pharmaceuticals, Inc LifeGlobal, Inc

UNLABELED/UNAPPROVED USES DISCLOSURE None

Discussion Outline


- 1. Consider the source of the oocytes we handle
- 2. Review requirements for optimizing the culture conditions
- 3. Discuss the rationale for extending culture to the blastocyst stage
- 4. Review the evidence for day 3 vs. day 5 transfer
- 5. Outline a protocol for selection of optimal day of transfer for each patient



Please indicate the percentage of your patients who have blastocyst transfer:

- A. Less than 10%
- B. Approximately 25%
- C. Approximately 50%
- D. Approximately 75%
- E. 100%


Source of the Oocytes: Follicle Growth & Selection



Day of Menstrual Cycle

Adapted from Hodgen '82

Ovarian stimulation & oocyte wastage



Ovarian stimulation typically results in a high number of abnormal, developmentally incompetent oocytes

The Goals of ART

- To maximize the likelihood of pregnancy for each patient
- To produce a healthy, genetically normal full-term delivery
- To minimize the risk of a multiple gestation



The Critical Questions are ...


• How can we achieve these goals for each patient by:

- > Optimizing the culture conditions
- Choosing the optimal day to transfer AND
- Selecting the most developmentally competent embryo available

Our culture systems are very complex!

The Complexity of the Culture System

- Culture dish
- Embryo density
- Gas phase: O₂ tension
- Culture medium: type & protein
- Oil and "contact" materials
- Incubator type
- Culture platform
- Air quality




Outlet port

Controlled fluid flow .

The in vitro environment is quite different from that in vivo

The In Vivo vs. In Vitro Environments



In vivo environment is:

- Moist, not fluid
- Micro, not macro
- Moving, not stagnant
- Chemically dynamic, not static
- Epithelial surfaces are glycoprotein rich, not inert

Courtesy of Don Rieger

Current embryo culture systems are non-physiological and are likely to be sub-optimal


Requirements for Optimizing the Culture Conditions

Quality Management in the IVF Laboratory


| | t | | ENVIRC Materi | | | IT ir Quality | | | | |
|--------------------------|---|----------------------|------------------|--|---|----------------------|--------------------|-------|--|--|
| Policies & Procedures | Current, validated, implemented | | | | | | | | | |
| Equipment | Maintenance, performance, QC | | | | QUALITY MANAGEMENT: Control Assurance | | | | | |
| Personnel | Trained, certified, constantly monitored | | | | | Improv | ement | | | |
| Patient | Optimal sti | | | | | | | | | |
| | Gamete Collection | Gamete Processing | Insem ICSI | | ert eck | Embryo Eval/Selec | Embryo Transfer | Cryo | | |
| | | | | | | | BWH BRIGHAN | M AND | | |

WOMEN'S HOSPITAL

Quality Management (QM) in the IVF Laboratory




QM Program: Fertilization rate as an indicator





QM Program: Embryo development as an indicator



UCL=upper confidence limit, LCL =lower confidence limit

Oocyte Source and Optimizing the Culture System

Summary

- All the oocytes but 1 (or 2) in a retrieved cohort would have undergone atresia in a natural cycle
- A cohort of retrieved oocytes is typically heterogeneous in quality
- The embryology lab is challenged to identify the "best" oocyte/embryo and to optimize culture conditions
- An effective QM program, involving quantifiable indicators in the IVF lab, is mandatory


Rationale for Extending Culture



What are the key benefits of extended (i.e. blastocyst) culture?


- A. This improves embryo development
- B. This eliminates the non-viable embryos
- C. This helps embryologists choose the better embryo(s)

The Normal Human Preimplantation Timeline



Rationale for Extending Culture


Embryo Developmental Issues



Day 5 transfer allows self-selection of the morphologically "best" embryos


Rationale for Extending Culture

Embryo Developmental Issues




Day 5 transfer allows self-selection of the morphologically "best" embryos

Aneuploidy and Female Age in the Human



Rationale for Extending Culture

Embryo Developmental Issues




Culture to day 5 may allow for greater selection of euploid embryos

Fragouli et al., '00

Rationale for Extending Culture Uterine Issues

- Improved synchrony between embryonic stage and uterine environment: Disturbance due to elevated estradiol¹ and progesterone²
- Reduced uterine contractility with blastocyst transfer³
- Reduced risk of embryo expulsion⁴



Moore & Persaud '98; The developing human embryo

Blastocyst transfer confers advantages on uterine

¹Valbuena et al '01; ²Healy et al '16; ³Fanchin et al '01; ⁴Fanchin et al '09

Rationale for Extending Culture

Summary

- Self-selection of embryos results in:
 - Higher quality embryos developing to the blastocyst stage
 - A lower incidence of aneuploidy in developing embryos
- The uterine environment may be more favorable for blastocyst transfer
- Therefore, extended culture should enable transfer of fewer embryos of higher quality in a more receptive uterus
- Together, higher implantation rates and lower multiple birth rates should result following blastocyst transfer

What does the evidence from RCTs tell us?

What Is the Evidence For and Against Blastocyst Culture?

Live Birth Rate: Fresh Transfers (RCTs)

| | Day 5 | /6 | Day 2 | /3 | | Odds Ratio | Odds | Ratio | Risk of Bias |
|--------------------------------------|-------------|----------|-------------------------|-------|---------|--------------------|---------------------|-----------|--------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% Cl | M-H, Fixe | d, 95% Cl | ABCDEF |
| Brugnan 2010 | 22 | 55 | 21 | 52 | 8.8% | 0.98 [0.45, 2.13] | | — | |
| Devreker 2000 | 3 | 11 | 1 | 12 | 0.5% | 4.13 [0.36, 47.30] | | | ?? 🔴 🖶 🖶 🕒 |
| Elgindy 2011 | 52 | 100 | 35 | 100 | 11.4% | 2.01 [1.14, 3.55] | | | |
| Emiliani 2003 | 33 | 82 | 41 | 89 | 16.0% | 0.79 [0.43, 1.45] | | _ | |
| Fernandez-Shaw 2015 | 25 | 60 | 11 | 60 | 4.4% | 3.18 [1.39, 7.31] | | | |
| Frattarelli 2003 | 15 | 29 | 8 | 28 | 2.7% | 2.68 [0.89, 8.02] | + | | |
| Levitas 2004 | 3 | 23 | 3 | 31 | 1.5% | 1.40 [0.26, 7.66] | | | |
| Levron 2002 | 8 | 46 | 15 | 44 | 8.6% | 0.41 [0.15, 1.09] | | | ? • • • • • |
| Livingstone 2002 | 14 | 30 | 11 | 29 | 4.1% | 1.43 [0.51, 4.04] | | | |
| Papanikolaou 2005 | 38 | 80 | 23 | 84 | 8.0% | 2.40 [1.25, 4.60] | | | |
| Papanikolaou 2006 | 56 | 175 | 38 | 176 | 17.5% | 1.71 [1.06, 2.76] | · | | |
| Rienzi 2002 | 24 | 50 | 24 | 48 | 8.7% | 0.92 [0.42, 2.04] | | | |
| Van der Auwera 2002 | 24 | 70 | 17 | 66 | 7.8% | 1.50 [0.72, 3.15] | - | | ? |
| Total (95% CI) | | 811 | | 819 | 100.0% | 1.48 [1.20, 1.82] | | ٠ | |
| Total events | 317 | | 248 | | | | | | |
| Heterogeneity: Chi ² = 21 | .83, df= 10 | 2 (P = 0 |).04]; I ^z = | 45% | | | | 10 5 | <u>–</u> |
| Test for overall effect: Z = | : 3.68 (P = | 0.0000 | 2) | | | | | | - |
| | | | | | | Fave | ors day 2/3 | Favors da | y 5/6 |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | OR 1 | L.48; 9 | 95% CI = 1.20 | <mark>, 1.82</mark> | | |
| | | | | | | | | | |


Multiple Birth Rate: Fresh Transfers

| Study or subgroup | Day 5/6 n/N | Day 2/3 n/N | Odds Ratio M-H,Fixed,95% Cl | Weight | Odds Ratio M-H,Fixed,95% Cl |
|------------------------------|----------------|----------------|--------------------------------|---------|--------------------------------|
| I equal number of embryos tr | | | H-H,HKeu,75% CI | | HH, I KEU, 75% CI |
| Bungum 2003 | 13/61 | 15/57 | - | 18.1 % | 0.76 [0.32, 1.77] |
| Coskun 2000 | 15/100 | 13/101 | + | 16.3 % | 1.19 [0.54, 2.66] |
| Hreinsson 2004 | 2/64 | 4/80 | _ - - | 5.1 % | 0.61 [0.11, 3.46] |
| Kolibianakis 2004 | 15/226 | 20/234 | + | 27.2 % | 0.76 [0.38, 1.53] |
| Papanikolaou 2005 | 18/80 | 8/84 | - | 9.0 % | 2.76 [1.12, 6.77] |
| Papanikolaou 2006 | 0/175 | 2/176 | - _ | 3.7 % | 0.20 [0.01, 4.17] |
| Rienzi 2002 | 9/50 | 7/48 | + | 8.7 % | 1.29 [0.44, 3.78] |
| Van der Auwera 2002 | 9/70 | 9/66 | + | 12.0 % | 0.93 [0.35, 2.52] |
| Subtotal (95% CI) | 826 | 846 | + | 100.0 % | 1.05 [0.75, 1.46] |
| | | | 0.002 0.1 1 10 500 | | |
| | | Fav | ors day 5/6 Favors da | ay 2/3 | |

Embryo Freezing: Per Retrieval

| Study or subgroup | Day 5/6 | Day 2/3 | Odds Ratio | Weight | Odds Ratio |
|--|----------------|---------------------|--------------------|-----------|---|
| Brugnon 2010 | n/N 42/55 | n/N 51/52 | M-H,Fixed,95% Cl | 3.4% | M-H,Fixed,95% CI 0.06 [0.01, 0.50] |
| Bungum 2003 | 36/61 | 54/57 | | 6.3% | 0.08 [0.02, 0.28] |
| Fernandez-Shaw 2015 | 39/60 | 33/60 | <u> </u> | 3.2 % | 1.52 [0.73, 3.17] |
| Gardner 1998 | 29/45 | 14/47 | | 1.3% | |
| | | | | | 4.27 [1.78, 10.24] |
| Hreinsson 2004 | 15/64 | 34/80 | | 6.3 % | 0.41 [0.20, 0.86] |
| Karaki 2002 | 22/80 | 35/82 | - | 6.9 % | 0.51 [0.26, 0.98] |
| Kolibianakis 2004 | 114/226 | 145/234 | - | 19.3 % | 0.62 [0.43, 0.91] |
| Levron 2002 | 12/46 | 25/44 | | 5.2 % | 0.27 [0.11, 0.65] |
| Motta 1998 | 15/58 | 45/58 | - | 9.1 % | 0.10 [0.04, 0.24] |
| Pantos 2004 | 16/81 | 79/162 | + | 11.6 % | 0.26 [0.14, 0.48] |
| Papanikolaou 2006 | 115/175 | 126/176 | + | 11.8 % | 0.76 [0.48, 1.20] |
| Rienzi 2002 | 18/50 | 42/48 | - | 7.5 % | 0.08 [0.03, 0.23] |
| Ten 2011 | 20/28 | 26/27 | <u> </u> | 2.1 % | 0.10 [0.01, 0.83] |
| Van der Auwera 2002 | 26/70 | 35/66 | - | 6.2 % | 0.52 [0.26, 1.04] |
| Total (95% CI) | 1099 | 1193 | ♦ | 100.0 % | 0.48 [0.40, 0.57] |
| Total events: 519 (Day 5/6), 74 | 14 (Day 2/3) | | | | |
| Heterogeneity: Chi ² = 82.95, d | | l ² =84% | | | |
| Test for overall effect: Z = 8.25 | | | | | |
| Test for subgroup differences. N | Not applicable | | | | |
| | | | 0.005 0.1 1 10 200 | | |
| | | Favors | day 2/3 Favor | s day 5/6 | |

Cumulative Live Birth Rate: Undefined # CETs



Fresh blastocyst versus cleavage transfers: Results

| | # | Day 5/6 | Day 2/3 | AOR |
|---|--------|--------------------|-------------------|----------------------|
| | Trials | Events/Total | Events/Total | (95% CI) |
| Live birth rate | 13 | 317/811 | 248/819 | 1.48 |
| (LBR) | | (39.1%) | (30.3%) | (1.20, 1.82) |
| Transfer cancellation rate (unselected patients | 17 | 108/1274 (8.5%) | 47/1303 (3.6%) | 2.50 (1.76, 3.55) |
| Multiple birth (equal # embryos transferred) | 8 | 81/826 (9.8%) | 78/846 (9.2%) | 1.05 (0.75, 1.46) |
| Embryo freezing | 14 | 519/1099 | 744/1193 | 0.48 |
| per retrieval | | (47.2%) | (62.4%) | (0.40, 0.57) |
| Cumulative LBR | 5 | 155/317 | 164/315 | 0.89 |
| (undefined # CETs) | | (48.9%) | (52.1%) | (0.64, 1.22) |


Cumulative Live Birth Rate: CETs within 1 yr of retrieval

| | SET Day 3 (n = 377) | SET Day 5 (n = 623) | P value |
|---|----------------------|----------------------|---------|
| Fresh cycles | 377 | 623 | |
| Transfer rate (%) | 370/377 (98.1%) | 588/623 (94.4%) | 0.004 |
| Deliveries with live birth per cycle ^a | 115 (30.5%) | 229 (36.8%) | 0.044 |
| Singletons | 115 | 225 | |
| Twins | 0 | 4 ^b | |
| FET cycles ^c | 329 | 325 | |
| Transfer rate (%) | 320/329 (97.3%) | 296/325 (91.1%) | 0.001 |
| Double embryo transfer cycles (%) | 156/320 (48.8%) | 91/296 (30.7%) | <0.001 |
| Deliveries with live birth per cycle ^d | 68 (20.7%) | 70 (21.5%) | 0.785 |
| Singletons | 62 | 62 | |
| Twins | 5 | 7 | |
| Triplets | I | I | |
| Cumulative live birth per patient | | | |
| Per innitiated fresh cycle ^e | 183/377 48.5% | 299/623 48.0% | 0.867 |
| Adjusted ^f | 51.8% | 45.9% | 0.103 |

Table II Treatment cycle live birth outcomes.

De Vos et al., '16

Cumulative Live Birth Rate: CETs within 1 yr of retrieval



The to pregnancy is shorter with blastocyst transfer

De Vos et al., '16

Monozygotic Twinning from Fresh Transfers

| | Incidence Day 3 | of MZ Twins Day 5 | Fold Increased Risk |
|---------------------|--------------------|----------------------|---------------------------|
| Rijinders et al '98 | 0.7% | 2.7% | 4.0 |
| Milki et al '03 | 2.0% | 5.6% | 2.8 |
| Da Costa et al '01 | 0.7% | 3.9% | 5.6 |
| Wright et al '04 | 0.4% | 1.5% | 3.8 |
| Behr et al '00 | | 5.0% | n/a |

Blastocyst transfer is associated with an increased risk of monozygotic twinning

Day 2/3 vs. Day 5/6: Monozygotic Twinning

Table II The association between **ART** parameters and monozygosity.

| | OR (95% CI) | aOR (95% CI) |
|---------------------|------------------|------------------|
| Embryo stage | | |
| Cleavage | Reference | Reference |
| Compaction | 0.63 (0.24–1.65) | 0.91 (0.34–2.38) |
| Early blastocyst | 2.20 (1.20–4.06) | 2.70 (1.36–5.34) |
| Advanced blastocyst | 1.73 (1.12–2.65) | 2.05 (1.29–3.26) |

OR, univariable logistic regression odds ratio; aOR, adjusted multivariable logistic regression odds ratio.

N= 6,103 clinical pregnancies following SET

Day 2/3 vs. Day 5/6: Monochorionic Twinning

| Day ET | ICSI | N (cases) | OR | 95% CI |
|--------|------|-----------|-------|--------------|
| 3 | Νο | 1326 (12) | 1.00 | Referent |
| 3 | Yes | 902 (18) | 1.87 | 0.88 - 3.97 |
| 5 | Νο | 245 (7) | 4.31 | 1.59 – 11.68 |
| 5 | Yes | 28 (4) | 24.42 | 7.03 – 24.42 |

Blastocyst transfer is associated with an increased risk of monochorionic twinning

Skiadas et al '08

Summary of Obstetrical Outcomes

| Outcome per Singleton Birth | # Studies/Subgroups | RR (95% CI) |
|--------------------------------|------------------------|------------------|
| Perinatal mortality | 3 | 1.48 (1.09-2.02) |
| Pre-term birth | 13 | 1.12 (1.02-1.23) |
| Very pre-term birth | 10 | 1.14 (1.04-1.24) |
| Large for gestational age | 7 | 1.12 (1.03-2.51) |
| Small for gestational age | 8 | 0.84 (0.75-0.94) |

However, the evidence for each of the above is of low/very low quality and most of the absolute incidences are very small

Martins et al., '16

Clinical and Obstetrical Outcomes from Day 3 vs. Day 5 ET

Summary

Day 5/6 transfers are associated with:

- An increase in live birth rate following fresh transfer
- No difference in the multiple birth rate
- An increase in monozygotic and monochorionic twinning rates
- A decrease in the number of embryos frozen
- No difference in cumulative live birth rate within 1 yr of retrieval
- A shorter time to pregnancy
- An increase in transfer cancellation rate in unselected patients
- Several adverse obstetrical outcomes, but absolute risks are low

However, the evidence supporting the above is of low/very low quality




Which of the following is blastocyst *versus* cleavage stage transfer associated with:


- A. An increased risk of monozygotic and monochorionic twinning
- B. An increase in live birth rate following fresh transfer
- C. A decrease in the number of embryos frozen
- D. A shorter time to pregnancy
- E. No difference in cumulative pregnancy rate within 1 year of the retrieval
- F. All of the above

Which Patients Should Have Blastocyst Culture?

Which Patients Should Have Blastocyst Culture?



Day 5 Biopsy Appears Not to Impact Implantation



- One of a sibling embryo pair was biopsied & the embryos transferred in pairs
- Conceptuses were DNA fingerprinted to determine whether implanted embryo was biopsied or not


Which Patients Should Have Blastocyst Culture?

What About non-PGT patients?

- A definitive answer remains to be determined
- Appropriately powered RCTs with current technologies are required to resolve this issue
- Because of the risk of having no blastocysts to transfer, an algorithm for transfer day should be used
- Patients should be counseled regarding the pros and cons of each transfer day

Algorithm for Patient Selection to Day 3 *versus* Day 5 Transfer

Prospective Selection of ET Day for Non-PGT Patients



Day 3 is recommended for patients with poor previous blastocyst formation Please answer "yes" to only one of the following. After listening to this lecture, do you think:

- A. All patients should have blastocyst transfer
- B. Selected patients should have blastocyst transfer
- C. No patients should have blastocyst transfer

Key Points: Blastocyst versus Cleavage Transfer

- Blastocyst culture requires that a lab is "in control" through implementation of a stable QM program
- The lab must have:
 - > An efficacious and reliable culture system
 - Adequate incubator space to keep all embryos safe
 - A proven vitrification protocol for blastocyst freezing
- Acknowledgment that extended culture increases costs to the laboratory

Key Points: Blastocyst versus Cleavage Transfer

The rationale for blastocyst culture rests on benefits from:

- Self-selection of those embryos capable of forming blastocysts (at least in vitro) and possibly some selection of euploid embryos
- Potentially improved uterine receptivity

Key Points: Blastocyst versus Cleavage Transfer

- Blastocyst transfer is associated with increased risks of monozygotic and monochorionic twinning, as well as some obstetrical and neonatal risks
- Blastocyst transfer is associated with a shortened time to pregnancy:
 - Emotional value and reduced costs to patients
- However, cumulative pregnancy rates between day 3 and day 5 transfer are very similar, if not identical
- If a lab offers blastocyst transfer, an ET algorithm is recommended


Final Comments

We have come a long way since the birth of Louise Brown nearly four decades ago

- We have a greatly improved understanding regarding:
 - The biology of human gametes and embryos, and the development of the pre-implantation embryo
 - The basic requirements in running an IVF laboratory, and in culturing embryos to the blastocyst stage
- We have also made great advances in ovarian stimulation and transfer protocols

More and more patients are leaving our clinics pregnant!! HOWEVER

H19 Expression in Mouse Embryos




It is currently unknown whether there are media-associated epigenome-wide alterations in human embryos during culture

Markert-Velker et al., '10

The Barker Hypothesis

A baby's nourishment before birth and during infancy, as manifest in patterns of fetal and infant growth, "programmes" the development of risk factors such as raised blood pressure and glucose intolerance that are key determinants of coronary heart disease



Barker DJ. Eur J Epidemiol. 2003;8:733-736



